Changing lifestyle and rising geriatric population are identified as chief drivers of the global osteoporosis treatment market. Fortune Business Insights in a report, titled “Osteoporosis Treatment Market Size, Share and Global Trend By Therapy Type (Bisphosphonates, Hormonal Therapy, Monoclonal Antibodies Medications, Selective Estrogen Inhibitors Modulators (SERM), Bone-Building Medications, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026,” offers key insights into the global market.
Some of the leading players operating in the osteoporosis treatment market are:
- Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG, Pfizer Inc
- DAIICHI SANKYO COMPANY, LIMITED
- Novo Nordisk A/S
- Amgen Inc
It analyzes the factors enabling growth in the market and threats restraining its trajectory. The report also covers some of the leading segments in the osteoporosis treatment market. It also studies in detail the impact of latest innovations in the market. Policies encouraging and restricting growth are studied in detail as well. To offer an executive-level blueprint, the report compiles information obtained from trusted resources in a comprehensive chapter-wise format. A section is exclusively dedicated to studying the competitive landscape of the market. The report, therefore, profiles some of the leading market players and studies in detail growth strategies adopted by them.
Key Segmentation of Osteoporosis Treatment Market:
- By Therapy Type
- Hormonal Therapy
- Monoclonal Antibodies Medications
- Selective Estrogen Inhibitors Modulators (SERM)
- Bone-Building Medications
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Geography
- North America (the USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Looming Patent Expiries Pose Threat
Despite the aforementioned growth opportunities, the market is facing challenges on account of the impending patent expiry of a few blockbuster drugs. Furthermore, competition is expected to rise for mainstream market players following the launch of generics. Nonetheless, FDA approvals will give significant impetus to the market in the coming years. Recently in April 2019, UCB and Amgen Inc., announced receiving FDA approval on EVENITY to offer treatment for post-menopausal women who are at a high risk of fracture.
North America Emerges as Lucrative Market for Osteoporosis Treatment
To offer a comprehensive overview, the report segments the global osteoporosis treatment market in terms of region into North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific. Of these, North America is expected to show high demand. According to the National Osteoporosis Foundation, nearly 10 million Americans suffer from osteoporosis. The number is forecast to rise considerably in the coming years, which explains the high demand for osteoporosis treatment in the region.
More Trending Topics from Fortune Business Insights: